Drug Profile
Research programme: mitosis inhibitors - Cyclacel Pharmaceuticals
Alternative Names: Mitosis inhibitors research programme - Cyclacel PharmaceuticalsLatest Information Update: 02 Apr 2008
Price :
$50
*
At a glance
- Originator Cyclacel Pharmaceuticals
- Class
- Mechanism of Action Mitosis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 02 Apr 2008 Discontinued - Preclinical for Cancer in USA (unspecified route)
- 28 Mar 2006 Xcyte Therapies has merged with Cyclacel to form Cyclacel Pharmaceuticals
- 16 Mar 2005 Cyclacel and Altana Pharma AG executed a research collaboration agreement on mitotic target identification